Connection

Richard Friedman to Venous Thromboembolism

Back to Details
This is a "connection" page, showing publications Richard Friedman has written about Venous Thromboembolism.
Richard Friedman
Connection Strength
3.179
Venous Thromboembolism
  1. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics. 2011 Oct; 34(10):795-804.
    View in: PubMed
    Score: 0.339
  2. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun; 11(3):299-306.
    View in: PubMed
    Score: 0.332
  3. Strengths and limitations of standards of care to guide the orthopedic surgeon in VTE prevention. Orthopedics. 2011 Feb; 34(2):121-8.
    View in: PubMed
    Score: 0.324
  4. New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery. Instr Course Lect. 2011; 60:291-300.
    View in: PubMed
    Score: 0.322
  5. Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):14-21.
    View in: PubMed
    Score: 0.315
  6. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
    View in: PubMed
    Score: 0.308
  7. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
    View in: PubMed
    Score: 0.292
  8. VTE prophylaxis after hip fracture surgery. Am J Orthop (Belle Mead NJ). 2008 Oct; 37(10):502; discussion 502-9.
    View in: PubMed
    Score: 0.276
  9. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
    View in: PubMed
    Score: 0.101
  10. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012 Nov; 130(5):818-20.
    View in: PubMed
    Score: 0.090
  11. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res. 2012 Aug; 130(2):147-51.
    View in: PubMed
    Score: 0.086
  12. Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty. 2012 May; 27(5):659-66.e5.
    View in: PubMed
    Score: 0.085
  13. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr; 105(4):721-9.
    View in: PubMed
    Score: 0.081
  14. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26; 358(26):2765-75.
    View in: PubMed
    Score: 0.068
  15. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.067
  16. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008 Jan; 24(1):87-97.
    View in: PubMed
    Score: 0.065
  17. Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer. Cancer Invest. 2015; 33(9):405-10.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.